Filing Flows

Filing Flows › Editas Medicine (EDIT) › Next earnings date

Editas Medicine (EDIT) earnings on Nov 9, 2026: what to expect

Editas Medicine (EDIT) is expected to report earnings on Nov 9, 2026 (estimated), tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.21 (−$0.25 to −$0.19, 7 estimates) on revenue of $4.5M, against −$0.28 and $7.5M a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 80% chance of beating next time.

Report dateNov 9, 2026 (estimated)
Days to go1
EPS estimate−$0.21
Revenue estimate$4.5M
Beat rate75%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Editas Medicine: revenue lines, growth year over year, Q2 2026Editas Medicine: revenue lines, growth year over year, Q2 2026Revenue+232%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.28 on revenue of $15.2M, against the analysts' −$0.21.

The last report

Editas Medicine reported revenue of $11.9M for the second quarter 2026 (+232% Y/Y), net loss $18.2M. How it makes money → · Every quarter →

Editas Medicine: EPS against the estimate, last 4 reportsEditas Medicine: EPS against the estimate, last 4 reportsEstimateReported−$0.38−$0.28Nov 25−$0.21−$0.06Mar 26−$0.24−$0.26May 26−$0.28−$0.15Aug 26
Latest (Aug 26): Estimate −$0.28, Reported −$0.15.

Editas Medicine's latest quarter

Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart follows the revenue to costs, profit and cash.

Questions

When does EDIT report earnings?

Editas Medicine is expected to report on Nov 9, 2026 (estimated).

What are analysts expecting from Editas Medicine?

EPS of −$0.21 and revenue of $4.5M for the quarter.

Does Editas Medicine usually beat earnings?

It beat the consensus EPS estimate in 75% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.